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A B S T R A C T
Objective: Self-poisoning with non-opioid analgesics presents a growing challenge to health care providers. We aimed to assess the impact of an 18-year age
restriction of OTC sales and a pack size restriction of non-opioid analgesics sold OTC in pharmacies on hospital-treated poisonings and poisoning severity measured
using biomarkers.
Methods: We applied a before and after design using interrupted time series analysis. Data on all poisonings recorded as hospital admissions were obtained during
2002–2015 and biochemical parameters from laboratory databases during 2011–2015, both covering the entire Danish population.
Results: The age restriction was followed by a 17% level reduction in admissions for non-opioid analgesic poisoning among young people age 10–17 years (RR 0.830;
95% CI 0.697–0.988; p< 0.036). After the pack size restriction, an instant level reduction of 18.5% (RR 0.815; 95% CI 0.729–0.912; p< 0.001) was observed for the
entire population. A 27% decrease in the number of poisonings with alanine transaminase levels (ALT) ≥ 210 U/L was observed (RR 0.734; 95% CI 0.579–0.931;
p = 0.011) followed by 40% decrease in biomarkers indicative of liver failure (RR 0.597; 95% CI 0.421–0.847; p = 0.004). We also observed similar reductions for
other poisonings such as psychotropics.
Limitations: Although declines in poisonings were observed after implementation of means restrictive measures, a causal link cannot be inferred.
Conclusion: Age and pack size restriction were assiociated with a reduction in the numbers of poisonings. This was also observed for pharmaceutical poisonings in
general, which might suggest a non-specific or spill-over effect.
1. Introduction
Emergency department and intensive care units treat an increasing
number of patients who have self-poisoned with non-opioid analgesics
(Gedeborg et al., 2017; Morthorst et al., 2016). High prevalence
of self-poisoning has been reported among depressed patients
(Bachmann, 2018; Bertolote et al., 2004) as well as in young, depressed
populations (Fleming et al., 2007; Qin et al., 2018). Paracetamol is
particularly frequently used in deliberate self-harm incidents involving
adolescents and young adult women (Carroll et al., 2015;
Geulayov et al., 2016). Links between availability of non-opioid an-
algesics over-the-counter (OTC) and hospital presentations with non-
opioid analgesic poisoning as well as deaths have been noted in
European studies (Gedeborg et al., 2017; O'Rourke et al., 2002). Among
the non-opioid agents, paracetamol is sold OTC in most countries and,
by large, ingested safely. However, for this specific agent doses ex-
ceeding daily recommendations bear the risk of hepatotoxicity
(Bunchorntavakul and Reddy, 2013). Given the risk of acute liver
failure due to paracetamol and multi organ failure also following severe
salicylate poisonings and the consequential substantial health care
burden of this (Bromer and Black, 2003), the need for restrictions on
non-opioid analgesic availability seems sensible but remains disputed
(Bateman, 2014; Hawton, 2002).
Many European countries, including the United Kingdom (UK),
France, Ireland, and Sweden, have restricted pack sizes of non-opioid
analgesics sold OTC in pharmacies (Morthorst et al., 2018). However,
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few evaluations of these efforts have been conducted (Bateman, 2009;
Gunnell et al., 2000). One exception is the UK pack size restriction that
was linked to fewer deaths by suicide due to paracetamol, admissions to
liver units and referrals to hepatic and transplant units (Hawton et al.,
2004; Hughes et al., 2003). Moreover, as many as 990 deaths might
have been prevented during the subsequent 11 years (Hawton et al.,
2013).
Conflicting findings have been reported for evaluations of pack size
restrictions based on biomarkers (Prince et al., 2000; Robinson et al.,
2000; Sheen et al., 2001); local studies examining the impact on blood
concentrations and biomarkers, such as liver enzymes (ALT and INR),
have shown reductions in severity of poisonings (Hawton et al., 2001;
Robinson et al., 2000). Some have reported slightly higher maximum
values of creatinine, a biomarker for kidney failure, and prothrombin
time post intervention (Prince et al., 2000) in spite a decrease in rates of
severe paracetamol poisonings as well as a reduction in median grams
ingested; while others found increased numbers of paracetamol tests
with values above 1.3 mmol/l (Sheen et al., 2001). Changes in severity
of non-opioid poisonings were observed as a decrease in mean levels of
salicylates and prothrombin ratios but no change in paracetamol levels
after the legislative change (Hawton et al., 2001). However, findings
were all restrained by short follow-up periods, some covering small
catchment areas, and few observations. To sum up, studies showed
fewer poisonings but opposite findings in relation to the severity of
these.
To limit the availability of non-opioid analgesics, two legislative
measures have been implemented in Denmark: an 18-year age purchase
restriction in 2011 and a pack size restriction for OTC sales in 2013.
Prior to the pack size restriction, as many as 300 tablets of paracetamol
or Ibuprofen were available OTC in pharmacies, while packages with 10
tablets of paracetamol (500 mg) or Ibuprofen (200 mg) were available
in non-pharmacy outlets. In Denmark, sales of mild analgesics corre-
spond to 105 and 102 Defined Daily Doses (DDD by WHO), yearly per
1000 inhabitant in 2013 and 2015, respectively (Data, 2020;
Schmidt et al., 2016).
The aim of this study was to evaluate the impact of these two in-
terventions on intentional and accidental self-poisonings in patients
treated at Danish hospitals. Secondly, we aimed to investigate the se-
verity of poisonings on biochemical and hepatic parameters by com-
paring blood tests before and after the legislation on OTC sales in
pharmacies. To our knowledge, the current study is the first to combine
nationwide hospital data as well as laboratory data to assess trends in
poisonings with non-opioid analgesics.
2. Methods
2.1. Setting and study population
A pre-post design was employed. The study period was from 2002 to
2015 and the population were patients treated for poisonings identified
with their Danish civil registration number (CPR); the CPR number is
unique and assigned to all Danish residents upon birth or immigration
(Pedersen, 2011). Universal tax paid health care in Denmark is freely
available for all people having a CPR number allowing for linkage of
national hospital data through the National Patient Register and the
Psychiatric Central Research Register (Erlangsen and Fedyszyn, 2015).
These have since 1994 applied the International Classification of Dis-
eases 10th (IDC-10) and since 1995 included contacts with emergency
departments and outpatient services.
National biochemical data were obtained by linking five regional
laboratory databases capturing blood samples taken routinely during
hospitalization for poisonings.
2.2. Exposures
Two legislative measures affecting the availability of non-opioid
analgesics were implemented in Denmark. First, an age restriction was
introduced to ensure that only persons aged 18 years or older could
purchase non-opioid analgesics OTC in both pharmacies and non-
pharmacy outlets on March 7th, 2011. In pharmacies, unrestricted
amounts were available, while a maximum of 10 tablets could be ob-
tained in non-pharmacy outlets (2017c). Second, on September 30th,
2013, OTC sales of non-opioid analgesics were restricted to 20 tablets in
pharmacies.
2.3. Outcomes
2.3.1. Register data
Our primary outcome of poisonings was defined as presentations to
emergency departments or hospitals with a poisoning by non-opioid
analgesics (ICD-10: T39 and X60), including both accidental and in-
tended poisonings of paracetamol, NSAIDs and aspirins (acet-
ylsalicylic). We collected information on presentations to both somatic
and psychiatric hospitals where a main or sub-diagnosis had indicated a
poisoning; a joint measure to elude under registration of intentional
self-poisoning (Morthorst et al., 2016).
A separate category of other poisonings covered all other pharma-
cological poisonings (ICD-10: T38 and T41-T50), including intended
self-poisoning by psychotropic drugs, drugs affecting the autonomic
nervous system, and other unspecified agents (ICD-10: X61, X63, X64)
as well as accidental poisonings. Given that opiate poisoning (ICD-10:
T40) can be related to substance misuse, it is often difficult to de-
termine the underlying intention, Therefore, this diagnosis was
omitted. A category of violent methods, consisting of suicide attempts by
hanging, drowning, firearms, explosives and fire, sharp objects, moving
objects, and unspecified methods (ICD-10: X70-X84), was also identi-
fied. The definitions of intentional and unintentional self-harm are
based on previous studies (Gasse et al., 2018; Morthorst et al., 2016),
which partially examined these as joint measures and likewise were
based on National Danish Registers with high validity (Schmidt et al.,
2019). The most frequently used analgesics in Denmark paracetamol,
aspirin and ibuprofen exist, apart from single preparations, only in
combination with low doses of caffeine and codeine as OTC products,
hence without risk of influencing potential toxic cases.
Data on deaths involving non-opioid poisonings, suicides, and toxic
liver disease were obtained from the Cause of Death Registry.
2.3.2. Laboratory data
Biochemical data from laboratory tests performed for individuals
recorded with a hospital contact due to a non-opioid analgesic poi-
soning (ICD-10: T39, X60), as defined above, were collected for the
period 2011–2015. As a part of the regular clinical workup on non-
opioid poisonings, certain standard tests are administered to determine
poison risk, namely plasma concentrations of paracetamol and salicy-
late (mmol/l), liver and renal function measures of alanine transami-
nase (ALT; U/L), coagulation factors II, VII, X (INR or; prothrombin
time), total bilirubin level (TBL; µmol/l) and creatinine (µmol/l)
(Grann et al., 2011). Peak values, i.e. the highest level measured during
admission, were preferred as measures as they provide indication of
severity and prognostic values. Using general guidelines (2017a;
Pakravan et al., 2008; Temple, 2006), we developed a set of hier-
archical severity measures to denote risk of toxicity and organ im-
pairment, for instance, toxic creatinine levels, which were indicative of
a poor prognosis in paracetamol poisonings. The toxic levels of para-
cetamol concentration and salicylate were considered as 1.3 mmol/l
and 3.5 mmol/l, respectively. The risk levels applied were: risk level I
(ALT ≥ 210 U/L), level II (ALT ≥ 1000), level IIIa+b (INR ≥ 1.54
ratio or TBL ≥ 50 µmol/l), level IV (ALT ≥ 1000 and paracetamol ≥
1.3 mmol/l) and level V (ALT ≥ 1000 and INR ≥ 1.54 ratio or ALT ≥
1000 and TBL ≥ 50 µmol/l), ranging from moderate to severe hepa-
toxicity with poor prognosis). Please see the eText box. The lower re-
ference value was used, when values of blood concentrations were
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listed with a sign (>) instead of a numeric value. We excluded can-
celled tests and results where jaundice (icterus) or haemolysis had been
recorded as text opposite to numbers. Biochemical data were available
for 20,470 episodes of non-opioid analgesics poisonings (T39) and 3912
episodes of intentional self-poisonings (X60). The total number of peak
values varied from 9095 for salicylate to 16,644 for ALT.
2.4. Ethical considerations
The study was approved by the Danish Data Protection Agency
(RHP-2013-022) and the Danish Health Authorities (3-3013-494/1).
2.5. Interrupted time series analysis
We applied a combination model of interrupted time series analysis
to assess whether the interventions might be linked to 1) an instant
level change (as an immediate effect), 2) trend change (a possible
suggesting that smaller packages being kept in households), or 3) a
combination of both (Lopez Bernal et al., 2016). Quasi-Poisson re-
gression models were fitted to number of monthly events. Since October
2001, small packages of non-opioid analgesics (5 gs) have been avail-
able in other outlets than pharmacies; hence, the study period
2002–2015 was selected. Best-fitted models were constructed using the
following intervals: pre-intervention (January 2002–February 2011),
interim period (March 2011–September 2013), and post intervention
(October 2013–December 2015). Data on biomarkers were divided into
33 months before and 27 months after the pack size restriction where
data were available. The trend within each interval was estimated by
rate ratios [RR] comparing the relative change in rates per year with
95% confidence intervals (estimated from monthly data)
(Humphreys et al., 2017). Ratios of rate ratios [RRR] were employed to
assess the relative difference in trends in different intervals. The model
allowed for an instant level change quantified using rate ratio to
compare the rate after to before the interventions. Residual auto-
correlation was assessed by examining deviance residual plots and the
partial autocorrelation functions. We found no evidence for auto-
correlation. Adjusting for seasonal variation by using Fourier terms did
not improve the model fit and was omitted (Lopez Bernal et al., 2016).
As correction for multiple testing was not performed, we opted for
complete transparency of testing by listing all calculated estimates with
their confidence intervals (eTables). Data management was handled in
SPSS 22 and SAS 9.4, while analyses were performed using the R
software.
3. Results
3.1. Hospital presentations
During 2002 to 2015, a total of 56,586 individuals, including
42,762 women (mean age 29.7 years; SD 17.4) and 15,824 men (mean
age 36.0 years; SD 18.9) presented to hospital with either intentional or
accidental non-opioid analgesics poisonings.
As seen in Fig. 1a, there was no level change observed for non-
opioid analgesics poisonings after the age restriction on OTC sales
(p = 0.244). However, a subsequent decrease in trend was noted
(p = 0.015) (eTable 1). At the time of the pack size restriction, an
instant level reduction in number of non-opioid poisonings per year of
18.5% (RR 0.815; 95% CI 0.729–0.912; p < 0.001) was estimated.
The trend in other poisonings showed significant level reductions of
10% (RR 0.899; 95% CI 0.856–0.945; p < 0.001) and 11% (RR 0.887;
95% CI 0.825–0.954; p= 0.001) after the age and pack size restriction,
respectively. We found no change in violent methods when comparing
pre-intervention versus interim period (p= 0.675) trends; however, the
pack size restriction was followed by a 28% level reduction (RR 0.719;
95% CI 0.580–0.890) in violent methods.
When stratifying by age, we found that the age restriction in mild
analgesic sales was primarily linked to a significant instant level change
of 17% reduction in non-opioid analgesic poisonings (RR 0.83; 95% CI
0.697–0.988; p = 0.036) among those aged 10–17 years, at whom the
intervention was directed. In addition, a significant decrease in other
poisonings of 18% was observed among adolescents (RR 0.822; 95%
0.691–0.978; p = 0.027) (Fig. 2b). No significant change was noted for
the older age group. As seen in Fig. 2a, a significant level change in non-
opioid analgesic poisonings was noted among adults after the pack size
restriction (RR 0.867; 95% CI 0.781–0.962; p = 0.007). This was also
the case for violent methods in the adult population (RR 0.716
0.572–0.896; p = 0.004) (Fig. 2c).
3.2. Biochemical parameters
3.2.1. Severity measures of poisonings
A significant change was noted in blood test results for paracetamol
concentrations above the toxic threshold of 1.3 mmol/l after the pack
size restriction (test for equal trends: p < 0.001) (Fig. 3a and b,
eTable 2), while this was not the case for the salicylates level, by the
toxic threshold of 3.5 mmol/l (test for equal trends: p = 0.91). The
Figs. 4a-g illustrate the number of poisonings with peak values above a
threshold of toxicity and estimated events before and after the pack size
restriction. Concerning risk of renal impairment, the yearly trend in the
rate of creatinine levels above 120 µmol/l was 1.240 (95% CI
1.114–1.381) changing to 0.795 (95% CI 0.676–0.937) after the pack
size restriction (test for equal trends: p < 0.001) (Fig. 4e).
For risk level I, there was a 26.6% level drop in the rate of ALT tests
with values above 210 U/L (RR 0.734; 95% CI 0.579–0.931;
p = 0.011), suggesting fewer severe non-opioid analgesic poisonings
after the intervention. Regarding risk level II, we observed an instant
reduction of 31.4% in the rate of tests with ALT values above 1000 U/L
(RR 0.686, 95% CI 0.494–0.953; p = 0.025). For INR and TBL values
above toxic threshold (risk level IIIa-b) no significant difference was
detected.
Regarding poisonings with risk of liver injury (risk level IV), there
was no evidence of a difference in trends nor level change after the
intervention. For risk level V, severe hepatoxicity with poor prognosis,
we noted a significant instant level reduction of 40.3% (RR 0.597,
0.421–0.847; P = 0.004) following the pack size restriction.
3.2.2. Deaths
The number of deaths due to accidental poisoning and suicides by
non-opioid analgesics did not change when comparing the 15 months
before and after the pack size restriction (accidental poisoning: 5 versus
5 deaths; suicide: 9 versus 10 deaths). Suicides involving intentional
self-poisoning by unspecified drugs were 42 versus 39 deaths before
and after, respectively. Hence, the numbers of suicide deaths and fatal
poisonings were too small for meaningful analysis.
4. Discussion
Using nationwide hospital and biochemical data, we found that the
monthly number of non-opioid analgesic poisonings decreased sig-
nificantly after both the age and pack size restriction. We also found
that there were fewer severe poisonings with risk of liver injury.
We found a 18.5% reduction in the number of non-opioid analgesic
poisonings per month following the pack size restriction. This is sup-
ported by reductions between 11% and 31% in emergency department
visits and admissions due to paracetamol poisoning noted in previous
studies (Hawton et al., 2001; Hughes et al., 2003) with even larger
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reductions for severe poisonings. (Hawton et al., 2004; Turvill et al.,
2000). The present study is seemingly the first evaluation of an im-
plemented age restriction.
The few studies, in which sub-group analysis have been conducted
by age, sex or drugs, have reported inconsistent results (Bateman et al.,
2003, 2006). We found a significant reduction in non-opioid analgesics
poisonings (T39) among youth aged 10–17 years following the age
restriction. Comparable effects have been reported for other drug poi-
sonings, such as anti-depressants, opioids and benzodiazepines
(Bateman et al., 2003; Turvill et al., 2000); although one study found a
significant increase in antidepressant and opioid poisonings, suggesting
a shift towards other poisonings (Bateman et al., 2003). In Denmark,
however, a decrease by poisonings by agents only available on pre-
scription occurred among adolescents following the age restriction. The
general decrease of all pharmaceutical poisonings among younger age
groups could be suggestive of a public health ‘up-stream’ preventive
effect of both legislative changes. Although the option of method sub-
stitution has been hypothesized, it has not previously been examined
whether people at risk might divert to violent methods. Due to small
numbers, it cannot be determined nor excluded whether a substitution
to violent methods occurred among teenagers. As cutting was included
in this category, this could reflect an increasing tendency to use sharp
objects.
A decreasing trend in poisonings resulting in high blood levels of
paracetamol, i.e. indicative of toxicity, was noted after the pack size
restriction, while no trend differences or level change was found for
events with potential toxic salicylate concentrations. Comparable
findings have previously been shown for paracetamol levels
(Robinson et al., 2000) while early studies noted a decrease in salicylate
levels (Hawton, 2002; Hawton et al., 2001). In one study, paracetamol
concentrations remained unchanged (Sheen et al., 2001). Although
drug concentrations should be cautiously interpreted when not related
to time of ingestion, our findings suggest that the pack size restriction
led to a reduction in the number of severe poisonings with risk of liver
injury.
A previous study, which assessed impact of paracetamol pack size
restriction on biomarkers of liver function by examining median con-
centrations of liver enzymes 24–48 h after attending hospital, found no
change in ALT levels associated with paracetamol poisonings (23 before
vs. 23 U/L after) (Robinson et al., 2000). In this perspective, the de-
creased rate of poisonings with risk of renal impairment, liver injury
and severe hepatotoxicity noted in the present study is intriguing. Also,
the significant level change noted for ALT values above 210 and
1000 U/L immediately following the intervention and the 40% level
decrease in the number of events of the proxy for severe hepatotoxicity
provides robust evidence that fewer toxic test results were observed
Fig. 1. a–d Time-series-analysis of primary outcome as hospital contacts for non-opioid analgesics poisonings, intentional non-opioid analgesics poisonings, violent
methods and other poisonings during 2002–20151 .
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among patients treated after the pack size restriction; i.e. indicative of
lower levels of toxicity for poisonings treated in hospital.
It has been suggested that means restrictions might be followed by
method substitution. In this study, we did not find affirmative signs of
method substitution; on the contrary, we found a decreasing trend in
other poisonings. As this decrease was viewed to be unrelated to the
examined interventions, other explanations were sought. However,
authorities responsible for registers confirmed that registration proce-
dures had not been changed during the study period. Also, national
changes in doses of prescribed medication could not explain the ob-
served decline in other poisonings. Likewise, a potential positive impact
related to the establishment of the Danish Poison Information Centre
has not been demonstrated. Clinical health care providers may have
intensified their focus on preventing poisonings in general and
screening for suicide risk during admission (Sakinofsky, 2014) but this
does not seem to fully explain the trend. It could be a spill-over effect,
for instance, through increased awareness regarding safe storage of
household medication; similar effects have previously been noted for
other forms of means restriction, such as self-poisoning (Morgan et al.,
2005), jumping from high places (Reisch and Michel, 2005), and other
hotspot interventions (King and Frost, 2005). It is, however, possible
that the reductions we observed for other poisonings are the result of
factors unrelated to the intervention, such as other prevention policies
and socio-demographic changes, hence a potential source of con-
founding.
OTC sales of the examined drugs both in- and outside pharmacies
have previously been discussed (Bateman, 2009, 2014). A recent in-
vestigation of the association between sales of mild analgesics in
pharmacy and non-pharmacy outlets and the frequency of calls to
poison information centers, as a proxy for the severity of poisonings by
these agents, found that the lowest rates of paracetamol related calls
were found in those European countries where sales outside pharmacies
were not allowed (p = 0.02) compared to those allowing such sales in
supermarkets and at gas stations (Morthorst et al., 2016). However,
lliberalisation outside pharmacies, often implies even smaller packages
sold, as is the case in Denmark. An argument to support even fewer
household stocks.
5. Limitations
The major strengths of our study are the access to the national
hospital data and comprehensive laboratory data. Although the single
ICD-codes used here have not been validated, they have previously
been validated as joint measures (Gasse et al., 2018) to elude a risk of
Fig. 2. a–d Time-series-analysis of primary outcome as hospital contacts for non-opioid analgesics poisonings, intentional non-opioid analgesics poisonings, violent
methods and other poisonings during 2002–2015 by age groups1.
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under registration of intentional self-harm. The ICD-codes used in the
psychiatric and somatic registers are generally considered as valid and
have been tested for several different disorders (Schmidt et al., 2019).
The variety of laboratory tests and measures are unique and
strengthens the reliability of our findings. The inclusion criteria of both
accidental and intentional poisonings would capture all relevant cases.
The fact that there are no user fees associated with laboratory tests and
the electronic management of test results further enhances the validity
of the biochemical databases. Internal validity was secured through
laboratory guidelines, hence enabling a merge of lab systems (2014).
One limitation is that we could not address changes in severity of
other poisonings through the biochemical data obtained; due to the
diversity of pharmaceutical compounds in this group no unifying
measures could be established. Given that time since ingestion is highly
associated with plasma concentrations (Bunchorntavakul and
Reddy, 2013; Lee, 2017), it would have been desirable to have data on
time of ingestion. Clinical guidelines for N-acetylcysteine (NAC) treat-
ment following paracetamol poisonings in Denmark changed in Jan-
uary 2013 from a 36 to a 20 h intravenous regime, implying that fewer
blood tests were taken (2017b). Side-effects of NAC treatment, observed
as an increase in the INR values, might limit our risk level assessment
when using an INR < 1.54, though this remains disputed (Jang et al.,
2013; Owens et al., 2015). Nevertheless, this limitation was equally
present before and after the change in pack sizes. Furthermore, data on
Anatomical Therapeutic Chemical classification (ATC) codes, number
of tablets ingested and place of purchase as well as information on
accessibility of drugs in the household would have been desirable.
Possible confounders include extended opening hours of the Danish
suicide hotline, the Lifeline (Livslinien) since January 2014.
We opted to focus on 95% confidence intervals, as these can be
directly and meaningfully interpreted on the effect size scale (Tables 1
and 2).
6. Clinical implications
Universal suicide prevention strategies in the form of means re-
striction have been recommended as efficient in preventing deaths by
suicide (Zalsman et al., 2016). Implementation of such strategies de-
pends on public health legislation and are not straight forward to
evaluate (Morthorst et al., 2018). Nevertheless, a growing body of
evidence supports means restrictive efforts, ranging from limiting ac-
cess to hotspots to removal of potentially toxic drugs. Seemingly, the
strongest effects have been noted for suicide by jumping by restricting
access and installing awareness signs and hotline numbers at hotspots
(Zalsman et al., 2016). The second most efficient strategy was pack size
restrictions of analgesics, associated with a 43% reduction in suicide
deaths (Zalsman et al., 2016). In this study, we noted a reduction in the
numbers of hospital-treated poisonings and severe poisonings as mea-
sured by specific biomarkers from national laboratory data. However,
as we also found a reduction in poisonings with other drugs, it cannot
be excluded that the reduction in poisonings with non-opioid analgesics
was explained, at least partly, by other factors than the legislative
changes. It is also possible that the legislative changes might have had
an ‘up-stream’ public health impact observed as a general decrease in
overall poisoning patterns. We therefore recommend further testing in
other countries. Restrictive legislation should also include number of
packages allowed in one purchase in pharmacies.
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Fig 3. Plasma paracetamol toxic level _
1•3 mmol/l.
The red dotted line represents the pack
size restriction (September 2013).
Salicylate toxic level _ 3•5 mmol/l.
The red dotted line represents the pack
size restriction (September 2013). (For
interpretation of the references to color
in this figure legend, the reader is re-
ferred to the web version of this ar-
ticle.)
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